CSF1R and cancer: However, a phase 1b study (NCT02323191) assessed the anti-cancer activity, safety, pharmacodynamics, and pharmacokinetics of the anti-CSF1R monoclonal antibody emactuzumab in combination with atezolizumab in patients with advanced cancer who received immunotherapy.